1.	Clinical Trial to Assess the Efficacy and Safety of 'INNOCELL Immuncell-LC' With Temozolomide in Newly Diagnosed Glioblastoma of Korea Phase: Phase III Type: Treatment Status: Closed Age: 18 to 70 Sponsor: Pharmaceutical / Industry Protocol IDs: IcmLCBT_301, NCT00807027
2.	Biological Therapy in Treating Women With Stage IV Breast Cancer Phase: Phase II, Phase I Type: Treatment Status: Closed Age: 18 and over Sponsor: NCI, Other Protocol IDs: CDR0000069072, P30CA022453, WSU-2006-130, RWMC-0635146, WSU-010307M1F, WSU-0312004412, NCT00027807
3.	Phase I/II Study of Interleukin-12-Primed Activated T Cells in Combination With Fluorouracil, Sargramostim (GM-CSF), and Interferon alfa-2b in Patients With Metastatic Renal Cell or Colorectal Carcinoma Phase: Phase II, Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: Other Protocol IDs: STLMC-IMM-0104, L-01-108, STLMC-L-01108, NCI-V01-1686, NCT00030342
4.	GVAX in Advanced Prostate Cancer Patients Made Lymphopenic Phase: Phase II, Phase I Type: Treatment Status: Closed Age: 18 and over Sponsor: Other Protocol IDs: PPMC-EACRI-IRB-02-119, DOD Grant #DAMD17-03-1-0097, NCT00122005
5.	Local Treatment of Metastatic Melanoma With Autologous Lymphocytes and the Bispecific Antibody rM28 Phase: Phase II, Phase I Type: Treatment Status: Closed Age: 18 to 75 Sponsor: Other Protocol IDs: rM28-001, NCT00204594
6.	Phase I/II Randomized Study of Vaccination Comprising MART-1/gp100/Tyrosinase/NY-ESO-1/MAGE-3 Peptide-Pulsed Dendritic Cells Matured Using Cytokines in Combination With Autologous Lymphocyte Infusion With or Without Fludarabine in Patients With Chemotherapy-Naïve Metastatic Melanoma Phase: Phase II, Phase I Type: Treatment Status: Completed Age: 16 and over Sponsor: NCI Protocol IDs: MCC-13649, LAC-USC-10M-05-2, 6241, NCI-6241, LAC-USC-HS-05-00068, NCT00313508
7.	Autologous Cytokine-induced Killer Cell Adoptive Immunotherapy for Acute Myeloid Leukemia and Myelodysplastic Syndrome Phase: Phase II, Phase I Type: Treatment Status: Completed Age: 12 to 75 Sponsor: Other Protocol IDs: CIK#1/2006, NCT00394381
8.	Phase I/II Study of Autologous Stem Cell Transplantation after Chemotherapy and Immunotherapy Followed by Thalidomide in Patients With High-Risk or Refractory Multiple Myeloma Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Completed Age: 18 to 80 Sponsor: NCI Protocol IDs: MSGCC-0610-GCC, 0610 GCC, UPCC-0610-GCC, NCT00499577
9.	Phase I/II Study of Adoptive Immunotherapy Utilizing Activated Marrow Infiltrating Lymphocytes in Patients Undergoing Autologous Peripheral Blood Stem Cell Transplantation for Newly Diagnosed Stage II or III Multiple Myeloma Phase: Phase II, Phase I Type: Treatment Status: Closed Age: 18 and over Sponsor: Other Protocol IDs: JHOC-J0770, J0770, NCT00566098
10.	Daclizumab in Treating Patients With Newly Diagnosed Glioblastoma Multiforme Undergoing Targeted Immunotherapy and Temozolomide-Caused Lymphopenia Phase: Phase II, Phase I Type: Diagnostic, Treatment Status: Closed Age: 18 and over Sponsor: NCI, Other Protocol IDs: CDR0000579683, P50CA108786, P30CA014236, DUMC-PRO00000581, SPORE Project 3, Pro00000581, NCT00626483
11.	Phase I/II Study of Adoptive Immunotherapy Comprising 2-Methyl-3-Butenyl-1-Pyrophosphate-Stimulated Gamma Delta T Cells, Aldesleukin, and Zoledronate in Patients With Stage IV Renal Cell Carcinoma and Lung Metastases Phase: Phase II, Phase I Type: Treatment Status: Completed Age: 20 to 80 Sponsor: Other Protocol IDs: TRIC-CTR-GU-05-01, CTR GU 05-01, NCT00588913
12.	Therapy to Treat Ewing's Sarcoma, Rhabdomyosarcoma or Neuroblastoma Phase: Phase II, Phase I Type: Treatment Status: Temporarily closed Age: 19 months to 35 years Sponsor: NCI Protocol IDs: 070206, 07-C-0206, NCT00923351
13.	Chemotherapy and Peripheral Stem Cell Transplantation Followed By Immunotherapy in Treating Patients With Multiple Myeloma Phase: Phase II, Phase I Type: Treatment Status: Completed Age: 18 to 80 Sponsor: Other Protocol IDs: CDR0000256870, MSGCC-0065, UPCC-6401, NCI-V02-1709, NCT00046852
14.	Laboratory-Treated T Cells and Aldesleukin After Cyclophosphamide in Treating Patients With Stage IV Melanoma Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Completed Age: 18 to 75 Sponsor: Other Protocol IDs: 2179.00, NCI-2010-01281, FHCRC-2179.00, 6558, NCT00553306
15.	Phase I/II Study To Test The Safety and Efficacy of TVI-Brain-1 As A Treatment For Recurrent Grade IV Glioma Phase: Phase II, Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: TVI-AST-002, NCT01081223
16.	Phase II Pilot Study of Tumor-Specific p53 or ras Vaccines With or Without Cellular Immunotherapy With Peptide-Activated Lymphocytes Plus Interleukin-2 in Patients With Tumors Expressing Mutant p53 or ras Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: NCI-95-C-0105A, NCI-T94-0096N, T94-0096, NCT00019084
17.	A Pilot Study of Tumor-Specific Peptide Vaccination and IL-2 With or Without Autologous T Cell Transplantation in Recurrent Pediatric Sarcomas Phase: Phase II Type: Treatment Status: Completed Age: 30 and under Sponsor: NCI Protocol IDs: 970050, 97-C-0050, NCI-97-C-0050K, NCI-T96-0037, T96-0037, NCT00019279, NCT00001564
18.	Biological Therapy Following Surgery and Chemotherapy in Treating Patients With Stage III or Stage IV Breast Cancer Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI, Other Protocol IDs: CDR0000067236, WSU-C-1403-BR, NCI-G99-1561, NCT00004018
19.	Biological Therapy Following Surgery and Chemotherapy in Treating Patients With Stage II, Stage III, or Stage IV Lung Cancer Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI, Other Protocol IDs: CDR0000067238, WSU-C-1403-LU, NCI-G99-1562, NCT00004019
20.	Phase II Study of an Autologous Tumor Cell Vaccine and Adoptive Transfer of OKT3-Activated Autologous T Lymphocytes Following Surgery and Chemotherapy in Patients With Stage III or IV Colon Cancer Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: WSU-C-1403-CO, NCI-G99-1563, NCT00004020
21.	Phase II Study of an Autologous Tumor Cell Vaccine and Adoptive Transfer of OKT3-Activated Autologous T Lymphocytes Following Surgery and Chemotherapy in Patients With Stage III or IV Ovarian Cancer Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: WSU-C-1403-OV, NCI-G99-1564, NCT00004021
22.	Biological Therapy Following Surgery in Treating Patients With Stage III or Stage IV Melanoma Phase: Phase II Type: Treatment Status: Temporarily closed Age: 18 and over Sponsor: NCI, Other Protocol IDs: CDR0000067241, WSU-C-1403-ME, NCI-G99-1565, NCT00004022
23.	Phase II Study of an Autologous Cancer Cell Vaccine and Adoptive Transfer of OKT3-Activated Autologous T-Lymphocytes Following Surgery in Patients With Stage III or IV Renal Cell Carcinoma Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: WSU-C-1403-RN, NCI-G99-1566, NCT00004023
24.	Biological Therapy Following Surgery and Radiation Therapy in Treating Patients With Primary or Recurrent Astrocytoma or Oligodendroglioma Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI, Other Protocol IDs: CDR0000067243, WSU-C-1403-BT, NCI-G99-1567, NCT00004024
25.	Lymphocyte Re-infusion During Immune Suppression to Treat Metastatic Melanoma Phase: Phase II Type: Treatment Status: Completed Age: 16 and over Sponsor: NCI Protocol IDs: 990158, 99-C-0158, NCI-99-C-0158, NCI-T99-0078, T99-0078, NCT00019942, NCT00001832